News articles about Oncolytics Biotech (NASDAQ:ONCY) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncolytics Biotech earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.1639541610912 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/02/oncolytics-biotech-oncy-getting-somewhat-favorable-media-coverage-study-shows.html.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
What are top analysts saying about Oncolytics Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oncolytics Biotech Inc. and related companies.